1073241-49-2Relevant academic research and scientific papers
PROTEASOME INHIBITORS
-
Page/Page column 59, (2009/12/23)
Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as ca
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides
Manam, Rama Rao,McArthur, Katherine A.,Chao, Ta-Hsiang,Weiss, Jeffrey,Ali, Janid A.,Palombella, Vito J.,Groll, Michael,Lloyd, G. Kenneth,Palladino, Michael A.,Neuteboom, Saskia T. C.,Macherla, Venkat R.,Potts, Barbara C. M.
experimental part, p. 6711 - 6724 (2009/11/30)
Salinosporamide A (1 (NPI-0052)) is a potent, monochlorinated 20S proteasome inhibitor in clinical trials for the treatment of cancer. To elucidate the role of the chlorine leaving group (LG), we synthesized analogues with a range of LG potentials and det
